To receive all of the company’s financial communications in real time, please register directly by email at the following address: [email protected]
TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of new therapies for the treatment of cancer by targeting the tumor microenvironment (TME), today announces the success of a financing of up to 2 million euros. This financing extends the company’s financial visibility until December 2023 and will thus allow the company to reach its next major inflection points and to continue its GLORIA phase 1/2 clinical study evaluating combination therapies using NOX- A12 in patients with newly diagnosed brain cancer (glioblastoma).